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Quality by Design (QbD) has become an integral part of biopharmaceutical process development and 
manufacturing.  To gain the enhanced process understanding required by QbD, a well-designed small scale 
model that accurately predicts behavior at manufacturing scale is essential. This process understanding should 
ideally be achieved with rapid, efficient experimentation to decrease both the time and cost required for 
development.  The ambr250 automated microscale bioreactor system has the potential to address all of these 
challenges.  By embedding the ambr250 into the upstream process development workflow, throughput can be 
dramatically increased allowing for greater exploration of parameter operating ranges and more complete 
process understanding.  However, the value of such microscale technologies hinges on their ability to accurately 
mimic manufacturing scale.  
  
We embarked on a study to demonstrate the applicability of the ambr250 (250 mL) as a small scale model for a 
2000-L single-use bioreactor (SUB).  We evaluated consistency of cell culture process performance from the 
ambr250 to 2000-L SUB scale along with intermediate scales such as our legacy small scale model (3-L glass 
stirred-tank reactors) and 50-L to 1000-L SUBs.  Scalability was assessed using two monoclonal antibody 
molecules expressed from different CHO hosts (CHO K1 and DG44) and cultivated in different media platforms 
(chemically-defined and yeastolate-containing) to ensure broad applicability of the small scale model.  
Engineering principles were applied to develop appropriate agitation and gassing strategies at each scale to 
ensure comparability, with a power input based scaling strategy performing the best. Based on both univariate 
and multivariate data analysis methods the ambr250 behaved comparably to both our legacy small scale model 
and the SUBs for the assets evaluated.  Areas of focus to further refine the ambr250 as a small scale model 
have also been identified. 
 
